BACKGROUND: Although endometrial carcinoma is the most common gynecological cancer, it only rarely metastasizes to the skin, with a reported prevalence of 0.8%. We report a case of an elderly lady who recently developed cutaneous metastases from an endometrial primary diagnosed 7 years earlier. OBJECTIVE: Our purpose was to determine if the oral administration of megestrol acetate would be effective in the treatment of uterine adenocarcinoma metastatic to the skin. METHODS: The index case was given oral megestrol acetate over a period of 9 months. Pre- and posttreatment skin biopsies were performed and analyzed. RESULTS: During treatment with megestrol acetate, the cutaneous metastases in the abdominal skin decreased in area to less than 10% of the pretreatment surface area correlating with a marked histopathologic decrease in adenocarcinomatous glandular structures. CONCLUSION: Megestrol acetate can be successfully utilized in the treatment of endometrial adenocarcinoma metastatic to the skin as well as ostensibly in the treatment of other progesterone-sensitive metastatic cutaneous carcinomas.
BACKGROUND: Although endometrial carcinoma is the most common gynecological cancer, it only rarely metastasizes to the skin, with a reported prevalence of 0.8%. We report a case of an elderly lady who recently developed cutaneous metastases from an endometrial primary diagnosed 7 years earlier. OBJECTIVE: Our purpose was to determine if the oral administration of megestrol acetate would be effective in the treatment of uterine adenocarcinoma metastatic to the skin. METHODS: The index case was given oral megestrol acetate over a period of 9 months. Pre- and posttreatment skin biopsies were performed and analyzed. RESULTS: During treatment with megestrol acetate, the cutaneous metastases in the abdominal skin decreased in area to less than 10% of the pretreatment surface area correlating with a marked histopathologic decrease in adenocarcinomatous glandular structures. CONCLUSION:Megestrol acetate can be successfully utilized in the treatment of endometrial adenocarcinoma metastatic to the skin as well as ostensibly in the treatment of other progesterone-sensitive metastatic cutaneous carcinomas.